Fedratinib-d9
Product Specifications
UNSPSC Description
Fedratinib-d9 (TG-101348-d9) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2][3].
Target Antigen
Apoptosis; Isotope-Labeled Compounds; JAK
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis;Epigenetics;JAK/STAT Signaling;Others;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=S(C1=CC=CC(NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=C1)(NC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O
Molecular Weight
533.73
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Geron I, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr;13(4):321-30.|[3]Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![BEND4 Antibody (N-term) [APR04035G]](https://cdn.genprice.uk/genprice/genprice3.png)
![BEND4 Antibody (N-term) [APR04035G]](https://cdn.genprice.uk/genprice/genprice2.png)
![BEND4 Antibody (N-term) [APR04035G]](https://cdn.genprice.uk/genprice/genprice5.png)